Hiroshi Yoshimoto
Presidente presso Hebei Jie Xi Bio-Products Co. Ltd.
Provenienza dei contatti di primo grado di Hiroshi Yoshimoto
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 17 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Hiroshi Yoshimoto tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Nomura Securities Co., Ltd.
 Nomura Securities Co., Ltd. Investment Banks/BrokersFinance Nomura Securities Co., Ltd. (NSC) is a wholly-owned brokerage subsidiary of Nomura Holdings, Inc. (TSE: 8604; NYSE: NMR). Headquartered in Tokyo, the firm was founded in 1925. NSC places a strong emphasis on research, both fundamental and quantitative. In addition to stock and bond underwriting, their activities include IPO and M&A advisory, wealth management, separately managed accounts, fund wrap services, prime brokerage and structured equity finance. Their clients include institutions, hedge funds, private banks and private equity funds as well as corporate clients and retail investors. | Investment Banks/Brokers | Analyst-Equity | |
GlaxoSmithKline KK
 GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables GlaxoSmithKline KK researches, develops, imports, manufactures and sells toiletry products. The company was founded on August 18, 1928 and is headquartered in Tokyo, Japan | Household/Personal Care | President Director/Board Member Comptroller/Controller/Auditor Director/Board Member | |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Hospital/Nursing Management | Chief Executive Officer | |
| KAWASAKI KISEN KAISHA, LTD. | Marine Shipping | Director/Board Member | |
| TOTETSU KOGYO CO., LTD. | Engineering & Construction | Director/Board Member | |
| University of Freiburg | College/University | Doctorate Degree | |
Barclays Securities Japan Ltd.
 Barclays Securities Japan Ltd. Investment Banks/BrokersFinance Part of Barclays PLC, Barclays Securities Japan Ltd. is a brokerage company based in Tokyo, Japan. Barclays Securities Japan provides brokerage services. The Japanese company was founded in 1987. Kentaro Kiso has been the CEO of the company since 2014. | Investment Banks/Brokers | Analyst-Equity | |
| MEDIPAL HOLDINGS CORPORATION | Medical Distributors | Chief Administrative Officer | |
| Universität Stuttgart | College/University | Graduate Degree | |
| École des Hautes Études Commerciales de Paris | College/University | Graduate Degree | |
Future Brain KK
 Future Brain KK Investment Banks/BrokersFinance Future Brain KK is a Japanese company that engages in securities dealing and real estate management business. The company is based in Tokyo, Japan. | Investment Banks/Brokers | President | |
| AISEI PHARMACY CO LTD | Drugstore Chains | Director/Board Member | |
Mediceo Corp.
 Mediceo Corp. Medical DistributorsDistribution Services Part of Medipal Holdings Corp., Mediceo Corp. is a Japanese company that wholesales drugs and medical devices. The company is based in Tokyo, Japan and was founded in 2004. | Medical Distributors | Director/Board Member | |
| Université Paris Nanterre | College/University | Undergraduate Degree | |
| REZOLUTE, INC. | Pharmaceuticals: Major | Director/Board Member | |
MEDIE Co., Ltd.
 MEDIE Co., Ltd. Internet Software/ServicesTechnology Services Part of Medipal Holdings Corp., MEDIE Co., Ltd. is a Japanese company that provides medical information through the internet and develops and distributes computer software and medical equipment and tools. The company is based in Tokyo, Japan. MEDIE Co. was acquired by Medipal Holdings Corp. on June 01, 2013 for $8.05 million. | Internet Software/Services | Director/Board Member | |
Sanofi-Aventis Groupe SA
 Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Sanofi-Aventis Groupe SA operates as a holding company, with interest in the manufacture and distribution of pharmaceutical products. The company was founded on December 19, 1995 and is headquartered in Paris, France. | Financial Conglomerates | Corporate Officer/Principal | |
Japan Vaccine Co., Ltd.
 Japan Vaccine Co., Ltd. BiotechnologyHealth Technology Japan Vaccine Co., Ltd. develops and markets preventive vaccines. The joint venture company is based in Tokyo, Japan. | Biotechnology | President | |
| SPLine Corp. | Director/Board Member | ||
| NOILE-IMMUNE BIOTECH INC. | Pharmaceuticals: Major | Director/Board Member | |
4BIO Ventures Management Ltd.
 4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
| JCR USA, Inc. | Director/Board Member Chief Executive Officer | ||
| Graduate School of Innovation & Technology Management | College/University | Corporate Officer/Principal | |
Luca Science, Inc.
 Luca Science, Inc. BiotechnologyHealth Technology Luca Science, Inc. is a Japanese preclinical stage biopharmaceutical company that specializes in mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs. Luca Science is based in Chuo-ku, JP, and was founded in December 2018 by Masashi Suganuma. The company uses its platform technology to manufacture, store, and deliver innovative mitochondrial drugs to research and develop therapeutics for unmet medical needs in a wide range of diseases for which there have been no effective treatments. The CEO is Rick C. Tsai. | Biotechnology | Director/Board Member |
Statistiche
Distribuzione geografica
| Giappone | 17 |
| Stati Uniti | 4 |
| Francia | 4 |
| Germania | 3 |
| Regno Unito | 2 |
Settori
| Finance | 7 |
| Consumer Services | 6 |
| Health Technology | 5 |
| Distribution Services | 3 |
| Consumer Non-Durables | 2 |
Posizioni
| Director/Board Member | 33 |
| Corporate Officer/Principal | 13 |
| Independent Dir/Board Member | 8 |
| President | 4 |
| Sales & Marketing | 4 |
Contatti più connessi
- Borsa valori
- Insiders
- Hiroshi Yoshimoto
- Connessioni Società
